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Abstract
Previous findings from this laboratory demonstrating changes in dopamine (DA) transporter and D2
receptors in the amygdaloid complex of subjects with major depression indicate that disruption of
dopamine neurotransmission to the amygdala may contribute to behavioral symptoms associated
with depression. Quantitative real-time RT-PCR was used to investigate the regional distribution of
gene expression of DA receptors in the human amygdala. In addition, relative levels of mRNA of
DA receptors in the basal amygdaloid nucleus were measured postmortem in subjects with major
depression and normal control subjects. All five subtypes of DA receptor mRNA were detected in
all amygdaloid subnuclei, although D1, D2, and D4 receptor mRNAs were more abundant than D3
and D5 mRNAs by an order of magnitude. The highest level of D1 mRNA was found in the central
nucleus, whereas D2 mRNA was the most abundant in the basal nucleus. Levels of D4 mRNA were
highest in the basal and central nuclei. In the basal nucleus, amounts of D4, but not D1 or D2, mRNAs
were significantly higher in subjects with major depression and depressed suicide victims, as
compared to control subjects. These findings demonstrate that the D1, D2 and D4 receptors are the
major subtypes of DA receptors in the human amygdala. Elevated DA receptor gene expression in
depressive subjects further implicates altered dopaminergic transmission in the amygdala in
depression.
Keywords
Dopamine receptor; gene expression; amygdala; depression; major depression; real-time PCR;
human brain; dopamine
1. Introduction
The dopaminergic system plays an important role in the regulation of motor, cognitive, and
emotional functions. Disturbances of the dopaminergic system have been strongly implicated
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in several neurological and psychiatric disorders, including Parkinson’s disease, schizophrenia,
and depressive disorders. Though most research on depressive disorders has focused on
serotonin and norepinephrine, there is vast array of compelling clinical and laboratory animal
evidence of a disruption of dopaminergic neuronal activity in depression (Dunlop and
Nemeroff, 2007; Kapur and Mann, 1992; Roy et al., 1992; Swerdlow and Koob, 1987). For
example, several drugs (neuroleptics, reserpine, α-methyl-p-tyrosine) that decrease
dopaminergic transmission are known to precipitate depressive episodes (Charney, 1998;
Willner, 1983a). In addition, low CSF concentrations of the dopamine (DA) metabolite,
homovanillic acid (HVA; see (Willner, 1983b) and reduced venoarterial plasma concentrations
of HVA have been reported in depression (Lambert et al., 2000). Consistent associations
between DA receptor polymorphisms and depression have not been found (Dunlop and
Nemeroff, 2007), although a recent metanalysis of 12 studies demonstrated a significant
association of a specific repeat polymorphism of the D4 dopamine receptor (DRD4.2) with
depression (López León et al., 2005). Results of neuroimaging studies of D2 receptor binding
in subjects with major depressive disorder (MDD) have not been consistent and are reviewed
by Dunlop and Nemeroff (2007). A recent functional magnetic resonance imaging study
demonstrated that subjects with MDD have a greater behavioral response to the rewarding
effects of amphetamine (Tremblay et al., 2005). In fact, the severity of depression correlates
with the magnitude of reward experienced by administration of amphetamine, a drug that
increases the synaptic availability of DA. This latter finding was used to argue that there is
reduced synaptic DA in depression, leading to postsynaptic supersensitivity including
supersensitivity to psychostimulants. The interpretation of postsynaptic supersensitivity is
likely to be an oversimplification of the pathological process in depression, because numerous
studies demonstrate that enhancement of D2-like receptor sensitivity is an important action of
antidepressant drug action (Gershon et al., 2007). Despite our lack of a thorough understanding
of DA pathobiology in depression, both preclinical and clinical findings suggest that brain
dopaminergic activity is reduced in depression.
A region of the brain that is richly innervated by DA and that has considerable relevance to
depression is the amygdala. The amygdala is involved in many emotion-laden behaviors and
stress-related responses associated with depression (Ramel et al., 2007; Whalen et al., 2002).
In fact, functional abnormalities in the amygdala correlate with the severity of MDD, i.e. resting
cerebral blood flow and metabolism correlate positively with ratings of depression severity. In
addition, antidepressant treatment reduces amygdala metabolism towards normal in MDD
patients (Drevets, 2003). Patients with MDD show a greater activation of the amygdala in
response to sad facial expressions, an effect that is attenuated by antidepressant treatment (Fu
et al., 2004; Surguladze et al., 2005). Abnormal amygdala volume has also been demonstrated
in MDD subjects, but consistent changes have not been observed across studies (Drevets,
2003), possibly because of unexpected familial and perhaps genetic influences on amygdala
size (Munn et al., 2007). Low glial cell density has been observed in postmortem amygdala
from MDD subjects (Bowley et al., 2002; Hamidi et al., 2004), as has been observed in the
prefrontal cortex (Rajkowska et al., 1999), suggesting that reduced glia support to neuronal
functions contribute to amygdala pathology in depression. Because of the important role of the
amygdala in emotion processing and the putative role of DA in depression pathology, we
previously investigated DA indices in postmortem amygdala from subjects with MDD. We
found an elevation of D2 DA receptors and a reduction of DA transporters in the amygdala of
subjects with MDD as compared to psychiatrically normal control subjects (Klimek et al.,
2002). Remy and coworkers (2005) observed lower [11C]RTI-32 binding (an in vivo marker
of DA and norepinephrine transporters) in the amygdala in depressed Parkinson’s patients
relative to non-depressed Parkinson’s patients, also implicating an association of a reduced
number of DA transporters (or reduced DA innervation) in the amygdala with depression.
Interestingly, administration of a DA neurotoxin that produces DA depletion results in
upregulation of D2 DA receptor s (Angulo et al., 1991) and a reduction in DA transporters in
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the rat brain (Gordon et al., 1996). Hence, postmortem receptor findings in MDD subjects
suggest that amygdala pathology in depression may be associated with deficient DA
transmission in the amygdala.
Five distinct subtypes of DA receptors mediate the actions of DA. D1 and D5 receptors belong
to the D1 subfamily, and D2, D3, and D4 represent the D2 subfamily; each receptor subtype
having a distinct pharmacological profile. DA receptors have been extensively characterized
with regard to the relative distributions of receptor proteins and mRNAs in a number of regions
of the brain (Hall et al., 1996; Kessler et al., 1993; Meador-Woodruff et al., 1996; Smiley et
al., 1994). However, few studies have concentrated on gene expression of DA receptors in the
subregions of the human amygdala, and gene expression levels of amygdala DA receptors in
depression have not been investigated. The present study aimed to clarify the quantitative
distribution of mRNA of the five subtypes of DA receptors in subnuclei of the human amygdala.
The present study also sought to determine whether D2 receptor upregulation in depression
observed previously (Klimek et al., 2002) may be related to an increase in D2 receptor gene
expression. In previous work, D2 receptor binding was highest in the basal amygdaloid nucleus,
a region where an elevation of D2 receptor binding and a decrease in DAT binding was
observed in MDD subjects as compared to normal control subjects. Hence, the basal nucleus
was the focus of the present investigation of DA receptor gene expression changes in
depression. The basal nucleus is part of the basolateral complex and is classically considered
a place of formation of conditioned and unconditioned stimulus associations in fear
conditioning, and plays a major role in regulating memory consolidation, particularly
emotionally charged memories (McIntyre et al., 2003). The basal nucleus also has reciprocal
connections with medial and orbital frontal cortex, areas where reduced activity has been
observed in MDD (Drevets, 2007). DA is known to enhance memory retention in the
basolateral amygdala (Lalumiere et al., 2004; LaLumiere et al., 2005) and putative altered
dopaminergic input to the amygdala could contribute to the link between disrupted processing
of emotionally charged stimuli and increased amygdaloid neural response that has been
observed in MDD subjects (Surguladze et al., 2005). The basal nucleus also communicates
directly with the major output nucleus of the amygdala, the central nucleus (Knapska et al.,
2007)), which projects to brainstem nuclei such as the locus coeruleus also known to be
dysregulated in MDD (Ordway, 2007).
2. Results
DA receptor mRNA distribution
Initial experiments determined the quantitative distribution of the 5 subtypes (D1–D5) of DA
receptor mRNA in five amygdaloid subnuclei (Figure 1), using tissue from seven
psychiatrically normal control subjects. All PCR reactions were validated for the specificity
of primers by melting curve analysis and agarose gel electrophoresis. DNA fragments with the
expected size are shown in agarose gel electrophoresis of PCR reactions for the five DA
receptors. In order to obtain copy numbers of the 5 DA receptor mRNAs, standard curves for
each subtype were established using the corresponding plasmid cDNAs (Figure 2).
D1, D2, and D4 mRNAs were expressed in the amygdala at markedly higher levels than were
D3 and D5 mRNAs (Figure 3), with the high expression genes (D1, D2, D4) differing in
concentration by approximately an order of magnitude from the low expression genes (D3 and
D5). Statistically significant differences in quantitative distributions of D1 F(4,30)=8.03;
p<0.0005), D2 (F(4,30)=21.7; p<0.0001), and D4 F(4,30)=3.63; p<0.05) receptor gene
expressions amongst the amygdaloid nuclei were observed. However, for the low expression
genes, D3 and D5, no significant difference in expression levels were observed among the
nuclei.
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The highest concentrations of D1 receptor mRNA were found in the central, lateral and basal
amygdaloid nuclei, where its concentrations were 4- to 7-fold higher than that in the accessory
basal and cortical nuclei. In contrast to D1 receptor gene expression, the expression of the D2
receptor gene was most abundant in basal amygdaloid nucleus, where its expression was
approximately 4- to 20-fold higher than that in the other amygdaloid nuclei. D2 receptor mRNA
was least abundant in the lateral nucleus, with intermediate levels of expression in the accessory
basal, cortical and central nuclei. D4 receptor gene expression was more evenly distributed
across the amygdaloid nuclei than were D1 and D2 receptor mRNA, although the basal and
central nuclei had the highest level of D4 gene expression.
DA receptor mRNAs in major depression
ΔDCT values for D1 and D2 receptor gene expressions did not significantly differ comparing
the normal control and MDD subject groups. The mean ΔCT value for D4 receptor mRNAs in
the basal nucleus of the amygdala from MDD subjects was significantly lower than that from
normal control subjects (p<0.03; Figure 4), indicating higher D4 mRNA levels in the MDD
group. Conversion of ΔCT values to fold changes (2−ΔΔCT; Livak and Schmittgen, 2001)
showed that D4 receptor gene expression was approximately 2-fold higher, respectively, in
MDD subjects as compared to control subjects. Although the common feature of all subjects
in the psychiatric group was MDD, two subjects with MDD did not die as a result of suicide.
The average ΔCT for D4 receptor gene expression of the two MDD subjects that did not die
by suicide was 2.5 cycles lower than the average of their two matched control subjects,
demonstrating that these two subjects had elevations in D4 mRNA very similar to the elevations
in the MDD subjects that died as a result of suicide.
Postmortem tissue variables, mRNA quality and quantitation
The possibility that variables unrelated to psychiatric status contributed to differences in gene
expression between depressive and control subjects was extensively considered. Study groups
were carefully matched for several parameters to reduce the influence of potentially
confounding issues. However, exact matching of all variables is not possible in postmortem
studies given the number of variables and the limitation of the availability of brain tissue from
suitable subjects. Postmortem intervals, pH values, and RIN values appear in Tables 1 (control
subjects) and Table 2 (depressed subjects). A summary of the averages of these values,
including ages, appears in Table 3. There were no statistically significant differences between
the 3 study groups comparing ages, PMIs, pH values, or RIN values.
Others have demonstrated an association between pH and RNA quality [34–36], drawing our
particular attention to these variables. No significant correlation between pH and RIN was
observed, even when all data were pooled from both study groups (r2 = 0.14; p > 0.05; Figure
5). This is likely related to the fact none of the brain tissues had pH values below 6.2. In our
experience, tissues with pH values below 6.0 often, but not always, have low quality RNA. In
addition, no correlations between PMI and RIN, or PMI and pH were observed. As expected,
RIN values were highly correlated with 18S/28S RNA ratios (r2 = 0.53, p < 0.0001; data not
shown), another related index of RNA integrity. Neither age, pH, PMI, nor RIN significantly
correlated with ▵Ct values for D1, D2 or D4 receptor gene expressions in either study group.
Finally, there were 3 subjects in the control group and 4 subjects in the MDD group that were
smokers at the time of death. Given the known effects of nicotine on DA neurotransmission,
we evaluated the possible association of the diagnosis of nicotine dependence on DA receptor
gene expression. Since there was a small number of smokers in both groups, we combined
control and MDD smokers and compared them to the combined control and MDD non-
smokers. There were no significant differences between these two groups for all 3 receptor
mRNAs (ΔCt values reported; D1: smokers 6.85 ± 0.29, non-smokers 7.52 ± 0.33; D2: smokers
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6.93 ± 0.28, non-smokers 6.85 ± 0.17; D4: smokers 7.82 ± 0.25, non-smokers 7.59 ± 0.29),
albeit the comparison of smokers to non-smokers in the MDD group is complicated by the fact
that there is a significant difference in D4 gene expression between controls and MDD subjects.
Nevertheless, the data do not support a relationship between nicotine dependence and DA
receptor gene expression in the basal amygdala.
3. Discussion
This study details for the first time the quantitative expression pattern of mRNAs for the 5 DA
receptors in the human amygdala subnuclei, using quantitative real-time RT-PCR. We confirm
previous identifications of DA receptor gene expression in the amygdala, demonstrate the
predominance of D1, D2 and D4 mRNA in the amygdala, and clarify the relative abundance
of the different receptor mRNAs in the various amygdaloid subnuclei. In addition, we report
elevated levels of D4 DA receptor mRNA in the amygdala from subjects with MDD as
compared to psychiatrically normal control subjects.
All 5 DA receptors are widely present in the brain including in the limbic system (Meador-
Woodruff et al., 1994). However, few previous studies have investigated the expression of
these receptors in the amygdaloid complex. Low levels of expression of the D1 receptor gene
have been found in basal and lateral amygdala using in situ hybridization (Hurd et al., 2001).
In the present study, both D1 and D5 mRNAs were observed in the amygdala, although D1
gene expression was much more robust. D5 receptor gene expression has been demonstrated
in several brain regions (Bouthenet et al., 1991; Choi et al., 1995; Huntley et al., 1992;
Rappaport et al., 1993), but has not been previously reported in the human amygdala. We found
D5 receptor mRNA to be expressed at low levels in all amygdaloid nuclei relative to D1
receptor mRNA. The low level of expression suggests that the D5 receptor may play only a
minor role in mediating DA signaling in the amygdala, although it is possible that this receptor
may be expressed abundantly on a small number of neurons and play a major role in DA
signaling on those neurons. This ambiguity is an inherent limitation of the method used to
quantify mRNAs in the present study.
Messenger RNAs for the D2-like receptors are expressed widely in the human brain (Bouthenet
et al., 1991; Jackson and Westlind-Danielsson, 1994), but only the D2 and D3 receptor mRNAs
have been previously reported in the human amygdala. In agreement with previous reports
(Hurd et al., 2001; Joyce et al., 1991), we found that D2 receptor mRNA was abundant in the
basal amygdala and expressed at lower levels in the lateral nucleus. D2 mRNA also was found
in the other subregions of amygdala including basal accessory, cortical, and central areas at
lower levels compared to the basal nucleus. Others have reported low levels of D3 receptor
mRNA in the human amygdala (Gurevich and Joyce, 1999; Murray et al., 1994). Gurevich and
Joyce (1999) found no detectable signal for the D3 receptor mRNA in the central nucleus,
using in situ hybridization. We found D3 receptor mRNA to be present in all amygdaloid nuclei,
including the central nucleus, albeit in relatively low concentrations in all regions. We used
RT-PCR to evaluate expression levels, a method capable of detecting very low expression
levels. Thus, the different techniques used to measure mRNA likely contributed to the
discrepancy in findings regarding D3 receptor mRNA between our study and that of Gurevich
and Joyce (1999). Similar to the D5 receptor, the level of D3 mRNA was considerably lower
than that of the D1, D2 and D4 receptor mRNAs.
D4 receptor mRNA has been observed in several brain regions (O'Malley et al., 1992; Van Tol
et al., 1991), but there is no previous description of D4 receptor mRNA in the human amygdala.
The present findings demonstrate robust expression of the D4 receptor gene throughout the
human amygdaloid nuclei, with levels of expression similar to the D1 and D2 receptor genes.
The level of D4 gene expression indicates that this receptor may play a significant role in
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transducing dopaminergic signaling in the amygdala. Most research investigating the D2 DA
receptor involvement in behaviors associated with the amygdala have used antagonists that
have high affinities for D2 and D3 receptors. Research designed to investigate the role of D4
DA receptor-mediated signaling in the amygdala is needed.
Using single photon emission tomography and [123I]iodobenzamide, an increase in D2 receptor
density in the striatum in depressed subjects has been reported (D'Haenen and Bossuyt,
1994; Shah et al., 1997), although no change in in vivo D2 receptor binding has also been
observed in depression (Parsey et al., 2001). We previously (Klimek et al., 2002) demonstrated
elevated [125I]epidepride binding to D2 receptors, reduced [125I]RTI binding to DA
transporter, and unchanged [3H]SCH 23390 binding to D1 receptors in amygdaloid subnuclei
(including the basal nucleus) from MDD subjects as compared to psychiatrically normal control
subjects. In these receptor studies, the specific D2-like subtype (D2, D3 or D4) of DA receptor
that was labeled by [125I]epidepride or the chemically related [123I]iodobenzamide was not
certain. The affinities of epidepride for D2 vs D4 receptors has not been published. In the
present study, D2 and D4 receptor mRNAs were found to be the predominant D2-like receptor
mRNAs in the amygdala, and D4 mRNA was significantly elevated in depressed subjects.
Based on the present study, translated D4 mRNAs (to receptor proteins) may have contributed
to the elevated binding of [125I]epidepride to D2-like receptors in the basal nucleus of the
amygdala reported previously (Klimek et al., 2002). No changes in D1 gene expression in the
amygdala reported here corroborate previous findings of no differences in D1 receptor binding
in the amygdala in depressive subjects (Klimek et al., 2002).
A large body of research implicates a deficiency of DA in the pathophysiology of depression
(Dunlop and Nemeroff, 2007), as well as a role of D2 receptors in the neurochemical disruption.
Drugs that block DA receptors or deplete DA can induce depressive symptoms (Berman et al.,
1999; Willner, 1983a; Willner, 1983b). Also, Parkinson’s disease (low brain DA) is associated
with a high incidence of depression (Leentjens et al., 2003; Lemke et al., 2004; Nuti et al.,
2004). DA agonists alleviate movement disorders but also elevate mood in depressed
Parkinson’s subjects (Lemke et al., 2005). In rats, acute stress increases DA release (Finlay et
al., 1995; Inglis and Moghaddam, 1999), while exposure to repeated stress reduces brain DA
concentrations, such as in the nucleus accumbens where sustained DA reductions are
temporally correlated with behavioral deficits modeling depression (Gambarana et al., 1999;
Mangiavacchi et al., 2001). Repeated antidepressant treatment normalizes DA deficits
produced by chronic stress (Gambarana et al., 1999). Exposure of rats to chronic social stress
results in increased D2, but not D1, receptor binding in specific brain regions (Lucas et al.,
2004) and imipramine treatment reverses chronic mild stress–induced anhedonia and
simultaneously reverses decreased D2, but not D1, receptor binding in the limbic forebrain that
is associated with decreases in the performance of rewarded behavior (Papp et al., 1994).
Besides chronic stress, pharmacological reductions of dopaminergic transmission (haloperidol
treatment, 6-hydroxydopamine lesions of mesencephalic dopaminergic neurons, or reserpine
treatment) results in elevations of D2 receptor protein and gene expression in the striatum and
nucleus accumbens (Angulo et al., 1991; Papp et al., 1994). Together, these laboratory animal
and clinical data urge the interpretation that elevated D2-like receptor binding (D'Haenen and
Bossuyt, 1994; Klimek et al., 2002; Shah et al., 1997) and gene expression (present study)
reflect deficient limbic dopaminergic transmission in depression. Alternative hypotheses could
also explain the present data. For example, elevated D4 gene expression may be pre-existing
in MDD subjects, e.g. as a result of polymorphic differences, rather than as a result of
compensation for reduced DA. The D4 DA receptor gene (DRD4) is polymorphic and one
polymorphism, a 48-base pair repeat that can have functional consequences, has received much
attention in psychiatry. The 3 most common repeat polymorphisms are DRD4.2 (2 repeats),
DRD4.4 and DRD4.7. DRD4.2 and DRD4.4 are associated with higher gene expression than
DRD4.7 (Schoots and Van Tol, 2003). A recent metanalysis demonstrated that the DRD4.2
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allele is a risk allele for depression symptommatology (Lopez Leon et al., 2005). Hence, an
increased prevalence of DRD4.2 (higher expression levels) in our MDD group, could have
resulted in fewer DRD4.7 subjects (lower expression levels) in this group, and could have
contributed to the observed increase in D4 mRNA in MDD.
Numerous in vivo studies demonstrate abnormalities of the amygdala in patients with MDD
(Rosso et al., 2005; Siegle et al., 2007) (see (Drevets, 2003) for review, with exception (e.g.
(Frodl et al., 2004)). Among neuronal circuits likely involved in the control of cognitive and
emotional processes that are disrupted in depression, are projections from the amygdala and
ventral tegmental area (dopaminergic) that converge in the medial prefrontal cortex, as well
as prefrontal cortical projections to the amygdala. Recent imaging studies implicate reduced
prefrontal cortical function that is linked to increased amygdala activity (Drevets, 1999; Siegle
et al., 2007). Interestingly, animal studies demonstrate that dopaminergic mechanisms
mediated by D1, D2, and D4 receptors, regulate the balance of excitatory and inhibitory
transmission in the basolateral amygdala and medial prefrontal cortex (Floresco and Tse,
2007). Hence, depression-associated changes in expression of DA receptors may contribute to
an imbalance of excitatory and inhibitory communication between the prefrontal cortex and
amygdala.
There are a number of shortcomings with regard to this study that deserve attention. One issue
not adequately addressed is whether DA alterations are associated with suicide behaviors that
are separate from those associated with depression. Suicide was the method of death in 9 out
of the 11 MDD subjects. The small number of subjects with MDD that died from natural causes
precluded analysis of suicide vs natural death within the MDD group. The issue of the biology
of suicide vs the biology of depression is one of the most difficult to investigate using
postmortem tissues because the majority of available and acceptable tissues (including the lack
of antidepressant drugs in toxicology) from depressed subjects who are depressed at the time
of death, at least in our experience, are from those who committed suicide. Another issue is
that 5 of the 11 MDD subjects had a history of antidepressant drug prescription. These drugs
were not found in their blood or urine at autopsy suggesting that the subjects were not compliant
with medication. Also, 4 of these 5 subjects committed suicide, which may have been
contributed to by non-compliance, inadequate dosing, and/or treatment refractoriness. Effects
of repeated antidepressant treatment on DA receptor mRNAs in the rat brain have been
reported, but effects are variable (increase, decrease or no change) depending on the type of
antidepressant, the receptor subtype, and the region of brain studied (Ainsworth et al., 1998;
Dziedzicka-Wasylewska et al., 1997; Dziedzicka-Wasylewska et al., 2002; Huzarska et al.,
2006; Kameda et al., 2000; Lammers et al., 2000). To our knowledge, DA receptor gene
expression in the amygdala following antidepressant drug treatment to rats has not been studied.
The small number of subjects with prescription histories precludes separate evaluation of the
MDD subjects having antidepressant prescription histories. It is worth noting that the ΔCt
values for D4 mRNA of these 5 MDD subjects ranged from highest to the lowest among all
subjects with MDD, pointing to no obvious relationship between prescription history and DA
gene expression levels.
The present findings demonstrate that the predominant DA receptor genes expressed in the
amygdala are the D1, D2, and D4 subtypes. Levels of gene expression of the D4 receptor are
elevated in the basal amygdaloid nucleus of depressed subjects relative to normal control
subjects. These latter findings, along with converging results from laboratory animal studies,
other human postmortem findings from depressed subjects, in vivo imaging studies in
depressed patients, and findings regarding the association of depression with Parkinson’s
disease, provide strong justification for further investigation of the role of DA in the
pathophysiology of depression.
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Human brain tissue was collected at autopsy at the Cuyahoga County Coroner’s Office in
Cleveland, Ohio, in accordance with an approved Institutional Review Board Protocol, as
described previously (Karolewicz et al., 2005). For the study of receptor mRNA distribution,
discarded brain tissues from 7 subjects (5 males, 2 females) were collected at autopsy and
detailed medication and psychiatric histories were unavailable. These subjects died as result
of cardiovascular disease (4), gastrointestinal disorder (1), aspirin overdose (non-suicide) (1)
and homicide (gun shot; 1). Based on autopsy records alone, there was no indication of
psychiatric or neurologic history. Subjects had an average age of 48 ±5 y (average ± S.E.M.),
an average postmortem interval of 22 ± 2 h, an average RNA integrity number (RIN; see below)
of 7.0 ± 0.3, and an average brain tissue pH of 6.43 ± 0.07. Psychoactive drugs (oxycodone
and ethanol) were detected in only one of these subjects.
For the study of relative gene expression levels in MDD, retrospective, informant-based
psychiatric assessments were performed for all depressed and control subjects. The Structured
Clinical Interview for DSM-IV Psychiatric Disorders (SCID-IV) or Schedule for Affective
Disorders and Schizophrenia: lifetime version (SADS-L) was administered to next-of-kin as
previously described (Stockmeier et al., 2002). Axis I psychopathologies were assessed and
consensus diagnoses were reached in conference using information from the interview and
medical records. Blood and urine samples from all subjects were examined by the coroner’s
office for psychotropic medications and substances of abuse. Psychiatric subjects available for
study included many that had antidepressant and antipsychotic medication in their toxicology.
However, only those subjects free of these drugs were used in the present study. Alcohol
dependent subjects with MDD were also available, but these subjects were also not included
in this study. Control subjects (2 females and 9 males) were individuals who acceded to natural
causes of death (Table 1). All control subjects had no Axis I psychiatric diagnosis at the time
of death and no history of an Axis I disorder, other than nicotine dependence, and no known
history of substance abuse. Major depressive subjects studied differed from our previous study
(Klimek et al., 2002) because of the lack of adequate amounts of tissue from subjects in the
previous study. The MDD group consisted of 11 subjects (3 females and 8 males) with active
MDD at the time of death, and who had died by natural deaths (2) and suicide (9) as listed in
Table 2. Subjects in the MDD group had no known history of substance abuse except for subject
KS32 who had a history of alcohol abuse, but was not alcohol dependent. Five of the 11 MDD
subjects had a history of antidepressant prescriptions (fluoxetine, sertraline, nortriptyline,
trazadone, buproprion) in medical records, but none of these subjects demonstrated positive
toxicology for antidepressants at autopsy, indicating non-compliance to medication or
termination of compliance prior to death. Other details of study subjects, not identified with
specific subjects, appear in Table 3 and in Results. Details of individual subjects are not aligned
in order to protect subject identities.
Dissection
Tissue blocks containing the amygdala were sectioned serially in the coronal plane beginning
at their anterior border. Histological sections (20 µm) were collected at 2 mm intervals. Sections
were processed for both Nissl staining and acetylcholinesterase (AChE) histochemistry (Sims
and Williams, 1990) to permit the identification of specific amygdaloid nuclei and dissections
of equivalent anatomical levels within these nuclei for all subjects (as performed in our previous
study (Klimek et al., 2002)). Amygdaloid tissue from the different nuclei was collected at the
point along its anterior-posterior extent where the basal nucleus is bifurcated (Mai et al.,
1997; see Figure 1). The central nucleus was found in the angle between the basal and accessory
basal nuclei and had no AChE reactivity. The lateral nucleus was easily distinguishable from
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the other nuclei. AChE-stained slides were held over the tissue block containing the amygdala
and a 25 gauge needle was used to mark the borders of the basal, accessory basal, and central
nuclei. Between 2 histological sections (representing 2 mm of tissue along the anterior-
posterior axis of the amygdala) at the point of bifurcation of the basal nucleus, 40 sections (50
µm) were collected and individual nuclei were dissected from each of the sections using a
tissue punch, storing the punches at −80°C until assayed. The bore of the punch was 5 mm for
the lateral nucleus, and 3.5 mm for all other nuclei.
RNA Preparation
Total RNA was extracted from tissue punches using RNAqueous Phenol-Free Total RNA
Isolation Kit (Ambion, Austin, TX). RNA samples were quantitated using a NanoDrop
ND-1000 Spectrophotometer (NanoDrop Technologies, Rockland, DE). The quality of RNA,
computed as RIN (Schroeder et al., 2006) was assessed with an Agilent 2100e Bioanalyzer
(Agilent Technologies, Santa Clara CA).
Recombinant plasmid DNA construction
cDNA fragments of DA receptor 1–5 (D1–D5) and the housekeeping genes β-actin and β2-
microglobulin were generated by reverse transcription with SuperScript III First-Strand
Synthesis System (Invitrogen, Carlsbad, CA) and PCR using Platinum PCR SuperMix System
(Invitrogen, Carlsbad, CA) with specific primer sets. Primers were designed to amplify regions
that were common to all known splice variants (Table 4). PCR products were subcloned into
the pCRII-TOPO TA cloning vector (Invitrogen, Carlsbad, CA). The sequence of each insert
was confirmed by restriction mapping and DNA sequencing reaction (Research Core Facility,
Dept. of Biochemistry, University of Mississippi Medical Center, Jackson, MS).
Real-time RT-PCR
Each sample of total RNA (0.5 µg) was DNase treated and reverse transcribed. RT minus
controls were used to identify any contaminating genomic DNA. One microliter of the resulting
cDNA was used as a template for real-time PCR using an iCycler (Bio-Rad, Hercules, CA)
with SYBR Green (Stratagene, La Jolla, CA) Amplification was carried out using gene specific
primers at a final concentration of 400 nM for the DA receptor and referernce genes. Each PCR
amplification was performed in triplicate wells using the following temperature and cycling
profile: 95°C for 10 min, 40 cycles of 95°C for 30 s, at the annealing temperature for 30 s
(specified in Table 4), and 72°C for 1 min. The cycle threshold value (CT) used to assess the
quantity of target gene was determined as the point at which the increased fluorescence
exceeded background fluorescence. For comparisons between control and MDD subjects,
cDNAs from paired samples were amplified simultaneously on the same plate. In order to
generate the standard curves to quantify each type of DA receptor mRNA in human amygdaloid
subnuclei, known amounts of recombinant DNA (see above) were 5-fold serially diluted and
then amplified. All samples cDNAs were measured in the range of the standard curve. The
copy numbers of cDNA from each DA receptor mRNA were calculated based on the
corresponding standard curve. Amplification efficiencies of primer sets ranged from 94% to
108%, except for D5 which was 125%. D5 was not used in the relative comparisons between
control and MDD subjects, i.e. not compared relative to reference genes. D5 mRNA
quantitation was estimated in the mRNA distribution study only using its own standard dilution
curve.
Data analysis
The quantitative distribution of gene expression of DA receptors in the amygdala was analyzed
using a one-way ANOVA. Post hoc comparisons between regions were made using the
Newman-Keuls Multiple Comparison Test (GraphPad Prism version 4.00 for Windows;
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GraphPad Software, San Diego, CA). For the analysis of expression data from depressed and
control subjects, CT values of DA receptor transcripts were normalized by subtracting the
geometric mean (Vandesompele et al., 2002) of the CT values of β-actin and β2-microglobulin
gene expressions generated from the identical reverse transcribed mRNA samples. Resulting
ΔCT values provided relative gene expression levels for DA receptor transcripts between study
groups. For calculation of fold-changes between control and MDD subjects, ΔCT values were
converted using the 2−ΔΔCT method (Vandesompele et al., 2002). Amplification efficiencies
of target genes and the reference genes were evaluated using linear regression analysis. Data
from major depressive and normal control subjects were statistically analyzed using an
unpaired Student t-test. Data are presented as mean ± S.E.M.
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Digital images of coronal sections of the human amygdala stained histochemically for
acetylcholinesterase. The left panel shows a complete section stained for acetylcholinesterase,
with amygdaloid nuclei labeled. The right panel illustrates a section stained for
acetylcholinesterase, following the tissue punching of nuclei for RNA extraction. The cortical
nucleus was close to the edge of the tissue block and a small piece of tissue on the upper side
has shifted during the section mounting. Abbreviations of amygdaloid nuclei are B basal, L
lateral, AB accessory basal, Co cortical, and Ce central.
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The real-time RT-PCR sensitivity and linearity analysis of standards for cDNAs each of the
five subtypes of DA receptor, derived from cloned cDNA plasmids. Standards for D1-like (left
panel; D1 ▲, D5 ○) and D2-like (right panel; D2 ■; D3 ▵; D4 □) receptor cDNAs were 5-fold
serial dilutions of the cloned cDNA standards starting from 35 to 1.11 × 105 molecules per
reaction amplified by the real-time PCR. The correlation coefficients (r2) of the 5 standard
curves were all greater than 0.99.
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Quantitative distribution of DA receptor gene expression in subregions of the human amygdala.
Amounts of mRNA were quantified by real-time RT-PCR. The mRNA copy number for each
DA receptor was calculated base on the standard curves shown in Figure 2. Abbreviations of
amygdaloid nuclei are as described in Figure 1. Some lines depicting the standard error of the
mean were drawn downward into the bars to aid in illustrating the distribution across all nuclei.
Asterisks indicate statistical significance between bars of comparison denoted by connecting
lines (* P < 0.05, ** P < 0.01, ***P < 0.001).
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Relative amounts of mRNA of DA receptors in the basal amygdaloid nucleus from
psychiatrically normal control subjects (n=11) and subjects with MDD (n=11), expressed as
either ΔCt (target gene minus reference genes; upper panels) or by fold change (2−ΔΔCt; lower
panels. Asterisks indicate statistically significant differences compared to control group (* P
< 0.05).
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Relationship between RNA integrity (RIN) and pH values in psychiatrically normal control
(○) and MDD (●) subjects. RIN values were not significantly correlated with brain tissue pH.
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Table 4
QPCR primers
Gene Primer Sequence Transcript Accession Number PCR Product (#bp) Annealing Temperature
DRD1 CTTAGGATGCTACAGACTTTGCCCTG NM_000794 149 57°CCATGTGGGATCAGGTAAACCAGATTG
DRD2 TCTTCGGACTCAATAACGCAGACC NM_016574 119 58°CGATGTAGACCAGCAGGGTGACAAT NM_000795
DRD3 GAGGTGACAGGTGGAGTCTGGAATTTC NM_033663 101 60°CGGCACAGAGATTAAGGATGCTGGCTG NM_000796
DRD4 CTGTGCTGGACGCCCTTCTTC NM_000797 118 60°CTTGAGGGCGCTGTTGACGTAG
DRD5 TGTCCATCCTCATCTCCTTCATTCC NM_000798 159 60°CCTGGAGTCACAGTTCTCTGCATTCAC
ACTB GCACCCAGCACAATGAAGATCAAG NM_001101 128 58°CTCATACTCCTGCTTGCTGATCCAC
B2M GTGCTCGCGCTACTCTCTCT NM_004048 85 57°CTCTCTGCTGGATGACGTGAG
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